» Articles » PMID: 35053608

A Few-Shot Learning Approach Assists in the Prognosis Prediction of Magnetic Resonance-Guided Focused Ultrasound for the Local Control of Bone Metastatic Lesions

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2022 Jan 21
PMID 35053608
Authors
Affiliations
Soon will be listed here.
Abstract

Magnetic resonance-guided focused ultrasound surgery (MRgFUS) constitutes a noninvasive treatment strategy to ablate deep-seated bone metastases. However, limited evidence suggests that, although cytokines are influenced by thermal necrosis, there is still no cytokine threshold for clinical responses. A prediction model to approximate the postablation immune status on the basis of circulating cytokine activation is thus needed. IL-6 and IP-10, which are proinflammatory cytokines, decreased significantly during the acute phase. Wound-healing cytokines such as VEGF and PDGF increased after ablation, but the increase was not statistically significant. In this phase, IL-6, IL-13, IP-10, and eotaxin expression levels diminished the ongoing inflammatory progression in the treated sites. These cytokine changes also correlated with the response rate of primary tumor control after acute periods. The few-shot learning algorithm was applied to test the correlation between cytokine levels and local control ( = 0.036). The best-fitted model included IL-6, IL-13, IP-10, and eotaxin as cytokine parameters from the few-shot selection, and had an accuracy of 85.2%, sensitivity of 88.6%, and AUC of 0.95. The acceptable usage of this model may help predict the acute-phase prognosis of a patient with painful bone metastasis who underwent local MRgFUS. The application of machine learning in bone metastasis is equivalent or better than the current logistic regression.

Citing Articles

Delivering Volumetric Hyperthermia to Head and Neck Cancer Patient-Specific Models Using an Ultrasound Spherical Random Phased Array Transducer.

Zubair M, Uddin I, Dickinson R, Diederich C Bioengineering (Basel). 2025; 12(1).

PMID: 39851288 PMC: 11760898. DOI: 10.3390/bioengineering12010014.


Artificial Intelligence in Detection, Management, and Prognosis of Bone Metastasis: A Systematic Review.

Papalia G, Brigato P, Sisca L, Maltese G, Faiella E, Santucci D Cancers (Basel). 2024; 16(15).

PMID: 39123427 PMC: 11311270. DOI: 10.3390/cancers16152700.


High Intensity Focused Ultrasound for Treatment of Bone Malignancies-20 Years of History.

Yeo S, Bratke G, Grull H Cancers (Basel). 2023; 15(1).

PMID: 36612105 PMC: 9817683. DOI: 10.3390/cancers15010108.


Neoadjuvant tislelizumab and tegafur/gimeracil/octeracil (S-1) plus oxaliplatin in patients with locally advanced gastric or gastroesophageal junction cancer: Early results of a phase 2, single-arm trial.

Yin Y, Lin Y, Yang M, Lv J, Liu J, Wu K Front Oncol. 2022; 12:959295.

PMID: 36158692 PMC: 9491115. DOI: 10.3389/fonc.2022.959295.

References
1.
Xiao Y, Jin Y, Hao K . Adaptive Prototypical Networks With Label Words and Joint Representation Learning for Few-Shot Relation Classification. IEEE Trans Neural Netw Learn Syst. 2021; 34(3):1406-1417. DOI: 10.1109/TNNLS.2021.3105377. View

2.
Takaki H, Cornelis F, Kako Y, Kobayashi K, Kamikonya N, Yamakado K . Thermal ablation and immunomodulation: From preclinical experiments to clinical trials. Diagn Interv Imaging. 2017; 98(9):651-659. DOI: 10.1016/j.diii.2017.04.008. View

3.
Guo Q, Zhang C, Guo X, Tao F, Xu Y, Feng G . Incidence of bone metastasis and factors contributing to its development and prognosis in newly diagnosed renal cell carcinoma: a population-based study. Cancer Manag Res. 2018; 10:2935-2944. PMC: 6118275. DOI: 10.2147/CMAR.S170083. View

4.
Vassiliou V, Andreopoulos D . Assessment of therapeutic response in patients with metastatic skeletal disease: suggested modifications for the MDA response classification criteria. Br J Cancer. 2010; 103(6):925-6. PMC: 2966620. DOI: 10.1038/sj.bjc.6605825. View

5.
Errico A . Surgery: MRgFUS-non invasive treatment for patients with painful bone metastasis. Nat Rev Clin Oncol. 2014; 11(6):303. DOI: 10.1038/nrclinonc.2014.86. View